RHYTHM PHARMACEUTICALS INC

For the period ended Sep 30, 2024. Filed Nov 6, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 6, 2024

RYTM$113.94+1.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)


· · September 30, · · December 31,
	2024		2023

Assets
Current assets: · ·
Cash and cash equivalents		$47,521		$60,081
Short-term investments		250,869		215,765
Accounts receivable, net		19,306		14,867
Inventory		13,895		8,624
Prepaid expenses and other current assets		8,750		8,931
Total current assets		340,341		308,268
Property and equipment, net		801		1,341
Right-of-use asset		3,588		781
Intangible assets, net		6,388		7,028
Restricted cash		462		328
Other long-term assets		11,992		14,999
Total assets		$363,572		$332,745
Liabilities, Convertible Preferred Stock and Stockholders’ equity
Current liabilities:
Accounts payable		$4,887		$4,885
Accrued expenses and other current liabilities		54,797		48,262
Other current liability - LG Chem		36,635		—
Deferred revenue		1,286		1,286
Lease liability		—		770
Total current liabilities		97,605		55,203
Long-term liabilities:
Deferred royalty obligation		109,241		106,143
Lease liability, non-current		4,030		490
Derivative liability		—		1,150
Total liabilities		210,876		162,986
Commitments and contingencies (Note 15)
Series A convertible preferred stock, $0.001 par value: 150,000 shares authorized; 150,000 and 0 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively. Liquidation preference of $150,000 as of September 30, 2024.		141,481		—
Stockholders’ equity:
Preferred stock, $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2024 and December 31, 2023		—		—
Common stock, $0.001 par value: 120,000,000 shares authorized; 61,436,251 and 59,426,559 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively		61		59
Additional paid-in capital		1,123,768		1,064,302
Accumulated other comprehensive (loss) income		(604)		134
Accumulated deficit		(1,112,010)		(894,736)
Total stockholders’ equity		11,215		169,759
Total liabilities, convertible preferred stock and stockholders’ equity		$363,572		$332,745

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.